Clicky

BioLineRx Ltd.(BLRX)

Description: BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company's development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.


Keywords: Biotechnology Pain Infectious Diseases Pharmacology Drug Discovery Autoimmune Disease Clinical Trial Clinical Development Acute Myeloid Leukemia Clinical Research Schizophrenia Jiangsu Inflammatory Bowel Disease Neuropathic Pain Nerve Treatment Of Acute Myeloid Leukemia Central Nervous System Disease Hematological Cancers Myocardial Infarction Pivotal Compugen Treatment Of Inflammatory Bowel Disease Biopharmaceutical Development Infarction Biolinerx Bl 5010 Polymer Solution

Home Page: www.biolinerx.com

BLRX Technical Analysis

Modiā€™in Technology Park
Hevel Modi'in, 7177871
Israel
Phone: 972 8 642 9100


Officers

Name Title
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA Chief Exec. Officer
Ms. Mali Zeevi CPA, CPA Chief Financial Officer
Dr. Ella Sorani Chief Devel. Officer
Mr. John Lacey Head of Corp. Communications & Investor Relations
Advocate Norman Kotler Internal Enforcement Officer, Gen. Counsel and Corp. Sec.
Ms. Liron Shemesh-Darvish M.B.A., Ph.D. Sr. Director & Head of Preclinical Devel.
Ms. Jael Birenberg M.Sc. Sr. Director & Head of RA, QA and PhV
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. Head of BD & Strategic Advisor
Ms. Holly W. May M.B.A. Pres of BioLineRx USA
Mr. Raziel Fried Treasurer & Budgetary Control Director

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.7645
Price-to-Sales TTM: 0
IPO Date: 2011-07-25
Fiscal Year End: December
Full Time Employees: 38
Back to stocks